Tactile Systems Technology, Inc. (NASDAQ:TCMD) VP Kristie Burns Sells 4,830 Shares

Tactile Systems Technology, Inc. (NASDAQ:TCMD) VP Kristie Burns sold 4,830 shares of the firm’s stock in a transaction on Monday, February 24th. The shares were sold at an average price of $14.65, for a total transaction of $70,759.50. Following the sale, the vice president now owns 84,008 shares in the company, valued at approximately $1,230,717.20. This represents a 5.44 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Tactile Systems Technology Trading Down 1.0 %

Shares of Tactile Systems Technology stock opened at $14.90 on Tuesday. The company has a fifty day simple moving average of $17.26 and a 200-day simple moving average of $15.71. Tactile Systems Technology, Inc. has a 12-month low of $11.12 and a 12-month high of $21.10. The company has a current ratio of 4.36, a quick ratio of 3.80 and a debt-to-equity ratio of 0.11. The stock has a market cap of $351.42 million, a price-to-earnings ratio of 21.29 and a beta of 1.20.

Tactile Systems Technology (NASDAQ:TCMD) last released its earnings results on Tuesday, February 18th. The company reported $0.40 EPS for the quarter, topping the consensus estimate of $0.31 by $0.09. Tactile Systems Technology had a net margin of 5.79% and a return on equity of 9.37%. The company had revenue of $85.59 million during the quarter, compared to analysts’ expectations of $85.39 million. On average, equities analysts forecast that Tactile Systems Technology, Inc. will post 0.7 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on TCMD. BTIG Research downgraded shares of Tactile Systems Technology from a “buy” rating to a “neutral” rating in a research note on Tuesday, November 5th. StockNews.com downgraded shares of Tactile Systems Technology from a “strong-buy” rating to a “buy” rating in a research note on Thursday, January 16th. Oppenheimer lowered shares of Tactile Systems Technology from an “outperform” rating to a “market perform” rating in a report on Tuesday, November 5th. Finally, B. Riley lowered shares of Tactile Systems Technology from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $23.00 to $18.00 in a report on Wednesday, February 19th.

Hedge Funds Weigh In On Tactile Systems Technology

Large investors have recently made changes to their positions in the stock. Creative Planning purchased a new stake in shares of Tactile Systems Technology during the third quarter worth about $187,000. Arcadia Investment Management Corp MI acquired a new stake in shares of Tactile Systems Technology in the third quarter worth approximately $29,000. Los Angeles Capital Management LLC boosted its position in shares of Tactile Systems Technology by 36.6% in the third quarter. Los Angeles Capital Management LLC now owns 135,796 shares of the company’s stock worth $1,984,000 after acquiring an additional 36,409 shares during the last quarter. Victory Capital Management Inc. acquired a new position in Tactile Systems Technology during the third quarter valued at approximately $180,000. Finally, Royce & Associates LP lifted its position in Tactile Systems Technology by 2.5% during the third quarter. Royce & Associates LP now owns 612,979 shares of the company’s stock valued at $8,956,000 after buying an additional 14,780 shares in the last quarter. Hedge funds and other institutional investors own 83.43% of the company’s stock.

Tactile Systems Technology Company Profile

Tactile Systems Technology, Inc, a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema in the home setting; and Entre Plus System, a portable pneumatic compression device for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers.